The Kansas City Clinical Oncology Program (KCCOP) expects to transition to NCORP-KC. It is a very successful non-profit organization conducting clinical trials in cancer therapy, cancer symptom prevention. Quality of Life, and cancer control since 1983 with uninterrupted funding by the National Cancer Institute. The program is located in the Kansas City metropolitan area and serves the needs of both Kansas and Missouri residents spread over 16 counties and 2.5 million citizens. The program is comprised of seven component area hospitals and 52 investigators representing specialties well beyond medical, surgical, gynecologic, and radiation oncology. The other areas of expertise include outcomes research, internal medicine, healthcare administration, healthcare informatics, behavioral science, rehabilitation and survivorship, palliative care, neurology, gastroenterology, genetic counseling, pathology, cellular therapy, laboratory science, and radiology. The program has provided participation opportunities to over 4,200 patients and volunteers in cancer-related trials since its inception. Over the last five years, an average of 235 new individuals have participated per year. The program has maintained excellent quality of research as confirmed by patient satisfaction and reports from external audits. The program derives its cancer trials from SWOG, NRG, ALLIANCE, CTSU, MD Anderson, URCC, and SunCoast research bases of the National Cancer Institute. NCORP-KC wishes to thank its participants and extend its service by entering a new era of Cancer Care Delivery Research while continuing to conduct high quality trials in cancer therapy, cancer control, screening, imaging, and post-therapy surveillance. The program monitors trends and implements measures for continued improvement. It balances protecting patients, their safety, and health with providing the broadest possible access to trial activation and minority outreach participation with the help of a highly responsive and responsible support staff.

Public Health Relevance

NCORP-KC supports the mission of the National Cancer Institute in accelerating the development of personalized therapies for cancer, minimizing or controlling symptoms related to therapies, identifying risk factors for cancer, and developing technologies for the early detection and prevention of cancer. NCORP-KC will achieve this by fostering a widespread participation of all stakeholders in clinical trials and cancer care delivey research. It will reach out to the entire Kansas City metropolitan area while promoting the participation of minorities, the elderly, and the underprivileged.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Clinical Research Cooperative Agreements - Single Project (UG1)
Project #
1UG1CA189853-01
Application #
8790673
Study Section
Special Emphasis Panel (ZCA1-RTRB-E (M1))
Program Officer
Xie, Heng
Project Start
2014-08-01
Project End
2019-07-31
Budget Start
2014-08-01
Budget End
2015-07-31
Support Year
1
Fiscal Year
2014
Total Cost
$587,757
Indirect Cost
Name
Kansas City Clinical Oncology Program
Department
Type
DUNS #
148680262
City
Prairie Village
State
KS
Country
United States
Zip Code
66208
Himelstein, Andrew L; Foster, Jared C; Khatcheressian, James L et al. (2017) Effect of Longer-Interval vs Standard Dosing of Zoledronic Acid on Skeletal Events in Patients With Bone Metastases: A Randomized Clinical Trial. JAMA 317:48-58
Bear, Harry D; Tang, Gong; Rastogi, Priya et al. (2017) The Effect on Surgical Complications of Bevacizumab Added to Neoadjuvant Chemotherapy for Breast Cancer: NRG Oncology/NSABP Protocol B-40. Ann Surg Oncol 24:1853-1860
Chung, Vincent; McDonough, Shannon; Philip, Philip A et al. (2017) Effect of Selumetinib and MK-2206 vs Oxaliplatin and Fluorouracil in Patients With Metastatic Pancreatic Cancer After Prior Therapy: SWOG S1115 Study Randomized Clinical Trial. JAMA Oncol 3:516-522
Sekeres, Mikkael A; Othus, Megan; List, Alan F et al. (2017) Randomized Phase II Study of Azacitidine Alone or in Combination With Lenalidomide or With Vorinostat in Higher-Risk Myelodysplastic Syndromes and Chronic Myelomonocytic Leukemia: North American Intergroup Study SWOG S1117. J Clin Oncol 35:2745-2753
Basch, Ethan; Dueck, Amylou C; Rogak, Lauren J et al. (2017) Feasibility Assessment of Patient Reporting of Symptomatic Adverse Events in Multicenter Cancer Clinical Trials. JAMA Oncol 3:1043-1050
Durie, Brian G M; Hoering, Antje; Abidi, Muneer H et al. (2017) Bortezomib with lenalidomide and dexamethasone versus lenalidomide and dexamethasone alone in patients with newly diagnosed myeloma without intent for immediate autologous stem-cell transplant (SWOG S0777): a randomised, open-label, phase 3 trial. Lancet 389:519-527
Moinpour, Carol M; Unger, Joseph M; Ganz, Patricia A et al. (2017) Seven-year follow-up for energy/vitality outcomes in early stage Hodgkin's disease patients treated with subtotal lymphoid irradiation versus chemotherapy plus radiation: SWOG S9133 and its QOL companion study, S9208. J Cancer Surviv 11:32-40
Heinrich, Michael C; Rankin, Cathryn; Blanke, Charles D et al. (2017) Correlation of Long-term Results of Imatinib in Advanced Gastrointestinal Stromal Tumors With Next-Generation Sequencing Results: Analysis of Phase 3 SWOG Intergroup Trial S0033. JAMA Oncol 3:944-952
Persky, Daniel O; Li, Hongli; Rimsza, Lisa M et al. (2017) A Phase I/II Trial of Vorinostat (SAHA) in Combination with Rituximab-CHOP in Patients with Newly Diagnosed Advanced Stage Diffuse Large B-Cell Lymphoma (DLBCL): SWOG S0806. Am J Hematol :
Stephens, Deborah M; Li, Hongli; LeBlanc, Michael L et al. (2016) Continued Risk of Relapse Independent of Treatment Modality in Limited-Stage Diffuse Large B-Cell Lymphoma: Final and Long-Term Analysis of Southwest Oncology Group Study S8736. J Clin Oncol 34:2997-3004

Showing the most recent 10 out of 12 publications